On July 28, 2025, Hengrui Pharma announced that it has authorized GlaxoSmithKline to have global rights outside of Greater China for HRS-9821 and options for up to 11 preclinical projects outside of Greater China.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/14f25930-b7a3-4a7c-bac0-e21999ae1ac1.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/14f25930-b7a3-4a7c-bac0-e21999ae1ac1.jpeg"/>
According to the agreement, GlaxoSmithKline will pay a $500 million upfront payment, option exercise fees, and milestone payments of approximately $12 billion, as well as a certain percentage of sales royalties.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/2c3b2167-b366-4329-aee0-6b4f51fd5aee.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/2c3b2167-b366-4329-aee0-6b4f51fd5aee.jpeg"/>
HRS-9821 is a potential best-in-class PDE3/4 inhibitor currently in clinical development, with opportunities for developing dry powder inhaler formulations.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/80fb962a-8036-4d7a-9e7c-3a6ab104b49c.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/80fb962a-8036-4d7a-9e7c-3a6ab104b49c.jpeg"/>
The other 11 projects cover multiple therapeutic areas including oncology, respiratory, autoimmune, and inflammation, all of which are in the preclinical research stage. Hengrui Pharma will lead the research and development until at least the completion of Phase I clinical trials, including data from overseas subjects.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/6ee697c7-a552-40bb-bb93-49b08b7c78e4.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/6ee697c7-a552-40bb-bb93-49b08b7c78e4.jpeg"/>
<h2>Summary</h2>
This transaction sets a new record for Hengrui Pharma's overseas licensing deals. Previously, the total amount for the GLP-1 product portfolio through Newco's overseas transaction was $6 billion, and the licensing of Lpa small molecules to Merck totaled $2 billion.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/97fb1304-82c5-44c7-b131-c5f1012a8309.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/97fb1304-82c5-44c7-b131-c5f1012a8309.jpeg"/>
Risk Warning and Disclaimer
The market has risks, and investments should be made cautiously. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at their own risk

600276

02359

01177

02367

01801

01877

Hengrui Pharma announced the global rights authorization of HRS-9821 and 11 preclinical projects to GSK, with a total transaction amount of USD 12 billion. GSK will pay a USD 500 million upfront payment and milestone payments. HRS-9821 is a potential PDE3/4 inhibitor currently in clinical development. This transaction sets a new record for Hengrui Pharma's overseas authorization, surpassing previous transactions of USD 6 billion and USD 2 billion

- On July 28, 2025, Heng Rui Medicine announced the licensing of global rights for HRS-9821 and up to 11 preclinical projects to GlaxoSmithKline.  
- GlaxoSmithKline will pay a $500 million upfront fee, approximately $12 billion in option exercise fees and milestone payments, along with a percentage of sales.  
- This transaction sets a new record for Heng Rui's overseas licensing deals, surpassing previous agreements involving GLP-1 and Lpa products.

Wallstreetcn

Hengrui Pharma

WUXI APPTEC

SINO BIOPHARM

GIANT BIOGENE

INNOVENT BIO

JUNSHI BIO

Record-breaking scale! $12 billion! Hengrui Pharma authorized PDE3/4 and other projects to GSK